HIV-associated facial lipoatrophy treated with injectable silicone oil: A pilot study - 17/08/13
![](/templates/common/images/mail.png)
Abstract |
Background |
Facial lipoatrophy (FLA) is associated with HIV infection and is part of the lipodystrophy syndrome. Temporary filler treatments do not meet the need of the patient, as there is a lack of permanence, and excessive cost.
Objective |
We sought to evaluate the safety and efficacy of a highly purified medical-grade 1000-cst liquid injectable silicone in the treatment of HIV-associated FLA using the serial microdroplet injection technique.
Methods |
Twenty patients with HIV-associated lipoatrophy were treated with liquid injectable silicone with a maximum of 6 treatment sessions (2.0 mL each session maximum). Patients were evaluated at 9-, 12-, and 18-month follow-up sessions. Safety, efficacy, injection volumes, and patient satisfaction were evaluated.
Results |
No persistent adverse effects were reported throughout the study. Most of the patients achieved complete correction of their HIV-associated FLA after 6 treatments and maintained this correction to the 18-month follow-up.
Limitations |
This is a noncomparative, nonblinded study. Study patient population size is small.
Conclusion |
Given our small sample size of 20 patients, our results suggest that, if administered correctly, liquid injectable silicone is potentially a safe, effective, and natural-feeling treatment option for HIV-associated FLA. Larger studies may be needed to confirm safety, efficacy, and permanence.
Le texte complet de cet article est disponible en PDF.Key words : facial lipoatrophy, HIV-associated lipoatrophy, liquid injectable silicone, permanent soft tissue filler, silicone oil
Abbreviations used : AE, CLSS, FLA, LIS, QOL
Plan
Supported by Richard James Development Inc, Peabody, MA. |
|
Conflicts of interest: None declared. |
Vol 69 - N° 3
P. 431-437 - septembre 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?